Faeth Therapeutics wins FDA fast-track status for PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer
FTH•FDA fast-track designation for PIKTOR combination
Faeth Therapeutics received FDA Fast Track designation for PIKTOR with paclitaxel in biomarker-selected advanced or recurrent endometrial cancer.
- No clinical results were reported or scheduled for presentation in the announcement.
- Fast Track status supports a faster regulatory path for patients whose disease progressed on platinum chemotherapy and an immune checkpoint inhibitor.
Related News
Dragonfly Energy partners with Sphere Energy to integrate AI into next-generation battery management systems
DFLI•
Mobix Labs forecasts fiscal Q4 revenue of $1.4 million-$1.8 million
MOBX•
